Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2025
New resource: understanding Canada’s drug approval and reimbursement pathway
3 December 2025 - Understanding how new oncology and non-oncology drugs move through Canada’s regulatory and drug access pathways can ...
Posted by Michael Wonder on 05 Dec 2025
Agenda for the December 2025 PBAC meeting
5 December 2025 - The agenda for the December 2025 PBAC meeting is now available. ...
Posted by Michael Wonder on 05 Dec 2025
Lecanemab in early Alzheimer's disease: previously unpublished data show no additional benefit
1 December 2025 - Based on previously unpublished data, the IQWiG concludes that lecanemab offers no proven advantage over the existing ...
Posted by Michael Wonder on 02 Dec 2025
Korea eases path to breakthrough drugs with flexible ICER rules
1 December 2025 - The Government has unveiled a large-scale overhaul of the health insurance drug pricing system, proposing flexible ...
Posted by Michael Wonder on 01 Dec 2025
Changes to NICE’s cost effectiveness thresholds confirmed
1 December 2025 - The Government has today announced that it will increase the thresholds NICE uses in evaluations of new ...
Posted by Michael Wonder on 26 Nov 2025
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
25 November 2025 - People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following ...
Posted by Michael Wonder on 21 Nov 2025
Alnylam's ATTR cardiomyopathy drug backed for NHS use
21 November 2025 - Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be ...
Posted by Michael Wonder on 20 Nov 2025
Welcoming Natalie McMurtry, Chief Executive of PHARMAC
19 November 2025 - In September Natalie McMurtry joined PHARMAC as our new Chief Executive. ...
Posted by Michael Wonder on 19 Nov 2025
Agenda for the March 2026 PBAC meeting (19 November 2025)
19 November 2025 - The agenda for the March 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 18 Nov 2025
High dose regimen of nusinersen receives positive CHMP opinion for the treatment of spinal muscular atrophy
17 November 2025 - Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen ...
Posted by Michael Wonder on 15 Nov 2025
CHMP positive opinion for Waskyra, a gene therapy for the treatment of Wiskott-Aldrich syndrome
14 November 2025 - Fondazione Telethon announces the positive opinion issued by the CHMP of the EMA, recommending marketing authorisation in ...
Posted by Michael Wonder on 15 Nov 2025
Highlights from the 10-13 November 2025 CHMP meeting
14 November 2025 - The EMA’s CHMP recommended ten medicines for approval at its November 2025 meeting. ...
Posted by Michael Wonder on 15 Nov 2025
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14 November 2025 - The EMA’s CHMP has adopted a positive opinion recommending the approval of Teizeild (teplizumab) to delay ...
Posted by Michael Wonder on 14 Nov 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – July 2025 PBAC meeting
14 November 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2025 PBAC ...
Posted by Michael Wonder on 12 Nov 2025
SMC - November 2025 decisions
10 November 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...